 ROCKVILLE, MD, July 25, 2022 GLOBE NEWSWIRE -- MacroGenics, Inc. Nasdaq: MGNX, a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the second quarter of 2022 after the market closes on Monday, August 8, 2022. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Monday, August 8, 2022, at 4:30 pm ET. 